文献速递中枢神经肿瘤放疗胸部肿瘤放疗姑息放疗与转移瘤

儿童癌症幸存者放疗后后续肿瘤风险:PENTEC综合综述

Risk of Subsequent Neoplasms in Childhood Cancer Survivors After Radiation Therapy: A PENTEC Comprehensive Review.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-09-29

该PENTEC系统综述分析了1975至2022年发表的83项中枢神经系统后续肿瘤、118项后续肉瘤和10项后续肺癌研究,评估放疗剂量与儿童癌症幸存者后续肿瘤风险的剂量反应关系及宿主与治疗因素的修饰作用。结果显示后续脑膜瘤、恶性中枢神经系统肿瘤、肉瘤和肺癌的每戈瑞超额相对比分别为0.44、0.15、0.045和0.068,且年轻诊断年龄与脑膜瘤和肉瘤风险升高相关,女性脑膜瘤风险高于男性。

要点

  • 后续脑膜瘤每戈瑞超额相对比为0.44(95%CI 0.19-0.68),恶性中枢神经系统肿瘤为0.15(95%CI 0.11-0.18)。
  • 后续肉瘤每戈瑞超额相对比为0.045(95%CI 0.023-0.067),后续肺癌为0.068(95%CI 0.03-0.11)。
  • 女性后续脑膜瘤风险高于男性(比值比1.46,95%CI 1.22-1.76,P<.0001),其他后续肿瘤未見统计学显著性别差异。

核心结论

  • 该PENTEC系统综述显示中枢神经系统后续肿瘤、肉瘤和肺癌均存在显著的放疗剂量反应关系。
  • 鉴于线性剂量反应,作者认为改善靶区适形性以限制高剂量体积可能是降低放疗后后续肿瘤风险的有前景策略。
  • 年龄和化疗等宿主与治疗相关因素在后续肿瘤发生中起显著促进作用,在评估儿童癌症幸存者放疗后后续肿瘤风险时应予以考虑。

研究设计与样本

  • 该研究为PENTEC针对已发表文献的系统综述,检索1975至2022年关于儿童癌症幸存者既往放疗后后续肿瘤的数据。
  • 摘要筛选后,从中枢神经系统后续肿瘤83项研究、后续肉瘤118项研究和后续肺癌10项研究中提取可用的定量与定性数据,后追加4项研究(中枢神经系统后续肿瘤3项、肺癌1项)。
  • 提取后续肿瘤发生率、放疗剂量、年龄、性别、原发癌症诊断、化疗暴露及从原发诊断到后续肿瘤的潜伏时间,采用逆方差加权线性回归分析每戈瑞超额相对比,并计算超额绝对风险。

主要发现

  • 后续脑膜瘤的每戈瑞超额相对比估计为0.44(95%CI 0.19-0.68)。
  • 恶性中枢神经系统肿瘤的每戈瑞超额相对比估计为0.15(95%CI 0.11-0.18)。
  • 后续肉瘤的每戈瑞超额相对比估计为0.045(95%CI 0.023-0.067)。
  • 后续肺癌的每戈瑞超额相对比估计为0.068(95%CI 0.03-0.11)。
  • 原发诊断时年龄较小与后续脑膜瘤和肉瘤风险较高相关,而暴露时年龄对恶性中枢神经系统肿瘤风险未见显著影响,肺癌相关年龄数据不足;女性后续脑膜瘤风险高于男性(比值比1.46,95%CI 1.22-1.76,P<.0001),其他后续肿瘤未见统计学显著性别差异;化疗(特别是烷化剂和蒽环类药物)与后续肉瘤风险存在关联,而特定化疗药物与中枢神经系统后续肿瘤和肺癌风险无明确关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A Pediatric Normal Tissue Effects in the Clinic (PENTEC) analysis of published investigations of central nervous system (CNS) subsequent neoplasms (SNs), subsequent sarcomas, and subsequent lung cancers in childhood cancer survivors who received radiation therapy (RT) was performed to estimate the effect of RT dose on the risk of SNs and the modification of this risk by host and treatment factors. METHODS AND MATERIALS: A systematic literature review was performed to identify data published from 1975 to 2022 on SNs after prior RT in childhood cancer survivors. After abstract review, usable quantitative and qualitative data were extracted from 83 studies for CNS SNs, 118 for subsequent sarcomas, and 10 for lung SNs with 4 additional studies (3 for CNS SNs and 1 for lung SNs) later added. The incidences of SNs, RT dose, age, sex, primary cancer diagnosis, chemotherapy exposure, and latent time from primary diagnosis to SNs were extracted to assess the factors influencing risk for SNs. The excess relative ratio (ERR) for developing SNs as a function of dose was analyzed using inverse-variance weighted linear regression, and the ERR/Gy was estimated. Excess absolute risks were also calculated. RESULTS: The ERR/Gy for subsequent meningiomas was estimated at 0.44 (95% CI, 0.19-0.68); for malignant CNS neoplasms, 0.15 (95% CI, 0.11-0.18); for sarcomas, 0.045 (95% CI, 0.023-0.067); and for lung cancer, 0.068 (95% CI, 0.03-0.11). Younger age at time of primary diagnosis was associated with higher risk of subsequent meningioma and sarcoma, whereas no significant effect was observed for age at exposure for risk of malignant CNS neoplasm, and insufficient data were available regarding age for lung cancer. Females had a higher risk of subsequent meningioma (odds ratio, 1.46; 95% CI, 1.22-1.76; P < .0001) relative to males, whereas no statistically significant sex difference was seen in risk of malignant CNS neoplasms, sarcoma SNs, or lung SNs. There was an association between chemotherapy receipt (specifically alkylating agents and anthracyclines) and subsequent sarcoma risk, whereas there was no clear association between specific chemotherapeutic agents and risk of CNS SNs and lung SNs. CONCLUSIONS: This PENTEC systematic review shows a significant radiation dose-response relationship for CNS SNs, sarcomas, and lung SNs. Given the linear dose response, improved conformality around the target volume that limits the high dose volume might be a promising strategy for reducing the risk of SNs after RT. Other host- and treatment-related factors such as age and chemotherapy play a significant contributory role in the development of SNs and should be considered when estimating the risk of SNs after RT among childhood cancer survivors.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Casey DL, Vogelius IR, Brodin NP, et al. Risk of Subsequent Neoplasms in Childhood Cancer Survivors After Radiation Therapy: A PENTEC Comprehensive Review. Int J Radiat Oncol Biol Phys. 2023. PMID: 37777927. doi:10.1016/j.ijrobp.2023.07.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。